HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.

Abstract
Despite incremental advances in the diagnosis and treatment for pancreatic cancer (PC), the 5‑year survival rate remains <5%. Novel therapies to increase survival and quality of life for PC patients are desperately needed. Epigenetic thera-peutic agents such as histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) have demonstrated therapeutic benefits in human cancer. We assessed the efficacy of these epigenetic therapeutic agents as potential therapies for PC using in vitro and in vivo models. Treatment with HDACi [suberoylanilide hydroxamic acid (SAHA)] and DNMTi [5‑AZA‑2' deoxycytidine (5‑AZA‑dc)] decreased cell proliferation in MiaPaCa2 cells, and SAHA treatment, with or without 5‑AZA‑dc, resulted in higher cell death and lower DNA synthesis compared to 5‑AZA‑dc alone and controls (DMSO). Further, combination treatment with SAHA and 5‑AZA‑dc significantly increased expression of p21WAF1, leading to G1 arrest. Treatment with epigenetic agents delayed tumour growth in vivo, but did not decrease growth of established pancreatic tumours. In conclusion, these data demonstrate a potential role for epigenetic modifier drugs for the management of PC, specifically in the chemoprevention of PC, in combination with other chemotherapeutic agents.
AuthorsJohana M Susanto, Emily K Colvin, Mark Pinese, David K Chang, Marina Pajic, Amanda Mawson, C Elizabeth Caldon, Elizabeth A Musgrove, Susan M Henshall, Robert L Sutherland, Andrew V Biankin, Christopher J Scarlett
JournalInternational journal of oncology (Int J Oncol) Vol. 46 Issue 5 Pg. 2223-30 (May 2015) ISSN: 1791-2423 [Electronic] Greece
PMID25695794 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Vorinostat
  • Decitabine
  • Azacitidine
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Azacitidine (analogs & derivatives, pharmacology)
  • Blotting, Western
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Decitabine
  • Disease Models, Animal
  • Female
  • Histone Deacetylase Inhibitors (pharmacology)
  • Humans
  • Hydroxamic Acids (pharmacology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Pancreatic Neoplasms (pathology)
  • Vorinostat

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: